CCAAT/enhancer-binding proteins (C/EBPs) are a family of transcription factors that regulate cell growth and differentiation in numerous cell types. To identify novel C/EBP-target genes, we performed transcriptional profiling using inducible NIH 3T3 cell lines expressing one of four members of the C/EBP family. Functional analysis revealed a previously unknown link between C/EBP proteins and circadian clock genes. Our microarray data showed that the expression levels of two core components of the circadian network, Per2 and Rev-Erb , were significantly altered by C/EBPs. Recent studies suggested that Per2 behaves as a tumor suppressor gene in mice. Therefore, we focused our additional studies on Per2. We showed that Per2 expression is upregulated by C/EBP and C/EBP . Per2 levels were reduced in lymphoma cell lines and in acute myeloid leukemia (AML) patient samples. In addition, we generated stable K562 cells that expressed an inducible Per2 gene. Induction of Per2 expression resulted in growth inhibition, cell cycle arrest, apoptosis and loss of clonogenic ability. These results suggest that Per2 is a downstream C/EBP -target gene involved in AML, and its disruption might be involved in initiation and/or progression of AML.
Introduction
The precise transcriptional regulation of numerous genes is required to maintain the balance between normal cellular proliferation and terminal differentiation. Such control is achieved through specific transcription factors that act as master regulators of various cellular functions. The CCAAT/enhancer-binding protein (C/EBP) family falls into this category of transcription factors, with many physiological and pathological conditions associated with their activities (1, 2) . To date, six C/EBP family members have been identified with further diversity achieved by the generation of different isoforms and extensive protein-protein interactions both within the family and with other transcription factors. All C/EBP family members contain a highly conserved basic region and a leucine zipper domain (bZIP). Tissue-and stage-specific expression, as well as variable DNA binding specificities contribute to the differences in the biological functions of the C/EBP isoforms.
C/EBP proteins play a key role in regulating proliferation and differentiation of many cell types including mammary epithelia cells, neuronal cells, granulocytes, hepatocytes, and adipocytes (3) . Increasing evidence now show that deregulated activity of some C/EBPs is involved in tumorigenesis (4) (5) (6) (7) . Within the hematopoietic system, C/EBP is crucial for granulocytic differentiation. It is expressed in hematopoietic stem cells and myeloid progenitors cells, and no mature granulocytes are found in C/EBP deficient mice (8) (9) (10) . Inactivation of C/EBP leads to a differentiation block in acute myeloid leukemia (AML), and conditional expression of C/EBP results in AML growth arrest and differentiation (11, 12) . In addition, mutations in the C/EBP gene are found in a subclass of human myeloid leukemias (13) (14) (15) , implicating it as a tumor suppressor For personal use only. on September 14, 2017 . by guest www.bloodjournal.org From gene. Furthermore, a variety of fusion proteins (i.e. AML/ETO, BCR/ABL, CBFB/MYH11 and PML/RAR) that result from chromosomal translocations in myeloid leukemia, either directly or indirectly, have been associated with inappropriately low expression of C/EBP (7, (16) (17) (18) (19) .
Circadian rhythms are generated by a set of clock genes organized in interlocking transcriptional-translational feedback loops. Circadian oscillations of clock genes are found in the suprachiasmatic nucleus (SCN), where the central pacemaker is located, and in many peripheral tissues including liver, muscle and bone marrow (20) (21) (22) . Recent studies provide evidence for molecular links between the circadian clock and cell proliferation (23, 24) . Many cell cycle-related genes are deregulated and cell cycle progression from S to M phase is impaired in mice lacking the Cry gene, a core component of the clock network (25) . Recent studies suggest that the murine Per2 gene, another key factor of the circadian system, is involved in tumor suppression by regulating cell cycle-and apoptosis-related genes (26) . In addition, disruption of circadian rhythms has been associated with cancer in humans (27) . Understanding the molecular links between the cell and the circadian cycle may lead to new therapeutic approaches to cancer as well as other challenging diseases.
In the present study, we used cDNA microarray analysis to examine the composition of C/EBP target genes following induction of C/EBP , C/EBP , C/EBP or C/EBP . Functional analysis of the data revealed a previously unknown link between C/EBP proteins and the circadian clock pathway. Further experiments focused on Per2 as a possible downstream target of C/EBP . We showed that C/EBP and C/EBP induced Per2 expression in hematopoietic cancer cell lines. Additional studies found low levels of
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Per2 expression in 42% of fresh AML bone marrow mononuclear cell samples. We also showed that reestablishment of Per2 expression in leukemia cells leads to dramatic growth inhibition, cell cycle arrest, apoptosis and reduced anchorage-independent cell growth. To our knowledge, this is the first study implicating abnormalities of Per2 associated with AML.
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Materials and Methods
Patient samples. Low-density mononuclear bone marrow cells from 21 AML patients as well as from 9 healthy individuals were obtained after their informed consent approval was obtained from Cedars-Sinai Medical Center institutional review board for these studies. Informed consent was provided according to the Declaration of Helsinki.
The samples were processed as previously described (28) . NIH 3T3 cells were transfected with zinc-inducible C/EBP vectors as well as control empty vector using the GenePORTER™ transfection Reagent (GTS Inc.). Multiple polyclonal clones were obtained by selection with G418 (700 µg/ml). Clones were screened by Western blot analysis for C/EBP protein expression following induction for 16 h with ZnSO4 (100 µM). The zinc-inducible Per2 expression vector (pMTPer2) was constructed by inserting a full-length V5-taggeted Per2 (generous gift from S. Lei, U.
Massachusetts Medical School, Worcester, MA) at the KpnI and EcoRV sites of the pMT vector. To generate stable inducible K562-pMTPer2, K562-pMT, Daudi-pMT , DaudipMT, KCL22-pMT , KCL22-pMT (12), U937-pMT and U937-pMT (29) cell lines, For personal use only. on September 14, 2017. by guest www.bloodjournal.org From K562, Daudi, KCL22 and U937 cells were transfected either with pMTPer2, pMT , pMT or pMT vectors using an electroporation apparatus (Electro Square Porator T820, BTX, San Diego, CA). Selection with G418 at 1 mg/ml was started 48 hours after electroporation to obtain stably transfected cells. Multiple monoclonal cultures were screened for zinc-inducible Per2, C/EBP or C/EBP expression by Western blot analysis.
Oligonucleotide array hybridization and data analysis. Triplicate clones of NIH 3T3 cells were induced by addition of ZnSO4 (100 µM) for 16 h to the medium.
Total RNA was isolated using TRIzol reagent (Invitrogen, Carlsbad, CA). Biotinylated cRNAs were prepared and hybridized to murine MG_74Av2 microarrays (Affymetrix, Santa Clara, CA, USA), which contains >12,000 genes. The probed arrays were scanned with a Hewlett Packard Gene Array scanner. The scanned output image files were analyzed using Affymetrix Microarray Suite version 5.0. To identify genes that were differentially expressed between the five-sample sets (empty vector, C/EBP , C/EBP , C/EBP and C/EBP ), class compression analysis was performed using BRBArray Tools (developed by Richard Simon and Amy Peng Lam; http://linus.nci.nih.gov/BRBArrayTools.html). Medium normalization was applied to the arrays, and the percent absent filter was set at 80% to exclude probe sets that were unreliable. A list of 158 genes was generated with probability of 95% that they contained no more then 10% false discoveries. Of these genes, 117 were significant at the 0.001 level of univariate F-test, and the remaining 41 were significant at the 0.027 level. Functional annotation analysis was performed using the Database for Annotation, Visualization, and Integrated Discovery (30) . were plated either into 24-well flat-bottomed plates using a two-layer soft agar system. After 14 days of incubation, colonies were counted and measured. Experiments were done at least twice using triplicate plates per experimental point. Statistical significance of the results was analyzed using t test.
Results

Transcriptional profiling of C/EBP-inducible NIH 3T3 cells
To identify C/EBP target genes, we generated a series of cell lines by stably transfecting NIH 3T3 cells with zinc inducible vectors that express either C/EBP (pMT ), C/EBP (pMT ), C/EBP (pMT ) or C/EBP (pMT ), as well as, a control empty vector (pMT). Following G418 selection and expansion, polyclonal populations of resistant cells were stimulated to express the C/EBP genes, followed by harvesting their RNA and protein. C/EBP protein expression was demonstrated by Western blot analysis using specific antibodies (Fig. 1A) .
To test the transcriptional activity of the C/EBP proteins, semiquantitative RT-PCR was performed using haptoglobin (Hp) and lipocalin (Lcn2), two known C/EBP target genes. Zinc treatment induced the expression of both genes (Hp, strong induction by C/EBP and low induction by C/EBP , C/EBP and C/EBP ; Lcn2, induction by C/EBP and C/EBP ), demonstrating that the stably transfected C/EBP proteins could specifically activate target genes that are normally expressed in other tissues (Fig. 1B) .
For global gene expression profiling, the transfected NIH 3T3 cell lines (3 independent polyclones from each stably transfected C/EBP family member) were cultured in the presence of zinc for 16 h. Oligonucleotide microarray analysis was performed with total RNA using Affymetrix U74Av2 chips. The raw expression data were processed and filtered according to the criteria described in "Materials and Methods". Using these criteria, we found that the expression of 158 genes was modulated in a statistically significantly fashion by one or more of the C/EBP proteins (supplementary data). These genes were classified into four functional categories (Table 1) . Consistent with previous knowledge about C/EBP functions, many of the differentially regulated genes are involved in regulation of cell growth, immune response, cellular metabolism and differentiation (3, (33) (34) (35) (36) (37) . Our analysis also showed that induction of C/EBP led to the most significant changes in gene expression, as well as, altering the largest number of genes.
Confirmation of microarray data
To verify the microarray results, the induction/repression of several genes was assessed by real time PCR (data not shown) and Northern blot analysis ( 
Per2 is a direct target for C/EBP and C/EBP
Functional annotation analysis showed that the expression levels of two core circadian genes, Per2 (Period 2) and Nr1d1 (nuclear receptor subfamily 1, group D, Analysis of the Per2 promoter region revealed that it contains several potential C/EBP binding sites between -1520 and -910 relative to the mRNA start site. We used reporter assays to examine whether C/EBP and C/EBP can regulate Per2 promoter activity. Cotransfection of NIH 3T3 cells with a Per2 promoter-luciferase construct, along with either the C/EBP or C/EBP expression vector resulted in a 7-and 5-fold stimulation of Per2 promoter activity, respectively (Fig. 3A) . Dbp, one of the genes identified by our transcriptional profiling, is a transcription factor that recognizes DNA binding sites similar to these recognized by C/EBPs (38) . We, therefore, tested the ability of DBP to activate Per2 transcription. Cotransfection of NIH 3T3 cells with the Per2 promoter-luciferase construct and a DBP expression vector led to a 3-fold increase in the reporter activity (Fig. 3A) . These results show that the Per2 promoter is induced by C/EBP , C/EBP and DBP.
Electrophoretic mobility-shift assays (EMSA) were performed to examine whether C/EBP can bind to its cognate site in the Per2 promoter. When a radiolabeled probe encompassing the putative C/EBP binding site was incubated with nuclear extracts from untransfected NIH 3T3 cells, only a weak band was detected (Fig. 3B ). In contrast, nuclear extracts from cells transfected with C/EBP expression vector gave rise to an intense band. The binding was specific as it was competed with unlabeled probe and addition of a C/EBP antibody supershifted the protein complex. This demonstrates that the transcriptional activation of Per2 is due to direct binding of C/EBP to the Per2 promoter.
We also performed chromatin immunoprecipitation (ChIP) experiments using murine bone marrow cells to determine whether C/EBP and C/EBP can directly bind to the Per2 promoter. The C/EBP and C/EBP antibodies, but not the negative controls (no antibody and preimmune serum), precipitated the endogenous Per2 promoter sequence. The -actin used as a control sequence, was not pulled down by the C/EBP antibodies ( Fig 3C) . These results indicate that C/EBP and C/EBP are specifically associated with the Per2 promoter in vivo.
Per2 is regulated by C/EBP and C/EBP in human hematopoietic leukemic cell lines
We next tested whether C/EBP and C/EBP can regulate Per2 expression in human hematopoietic cancer cell lines. For these experiments, we used chronic myelocytic leukemia, KCL22 and Burkitt's lymphoma, Daudi cell lines stably transfected with a zinc inducible C/EBP gene, as well as, a myelomonocytic leukemia, U937 cell line stably transfected with a zinc inducible C/EBP gene. Real time PCR analysis showed that Per2 expression levels increased by 7-and 5-fold following induction of C/EBP in the KCL22 and Daudi cell lines, respectively; and by 14-fold after induction of C/EBP in the U937 cell line (Fig. 4A) . We also measured the expression levels of Rev-Erb , the second clock gene identified by transcriptional profiling. Real time PCR analysis showed that Rev-Erb expression levels were downregulated by 2-and 4-fold following induction of C/EBP in the KCL22 and Daudi cell lines, respectively; and by 2-fold in the U937 cell line after induction of C/EBP (Fig. 4A) . This is in agreement and large B cell lymphoma (Sudhl6 and Sudhl16), Per2 levels were extremely low in comparison to levels in cell from normal human lymph nodes (Fig. 4B) . These results suggest that Per2 expression is downregulated in several subsets of lymphomas.
Inactivation of C/EBP often occurs in AML, and may subsequently result in deregulation of C/EBP target genes. We, therefore, tested whether Per2 might be abnormally expressed in patients with AML. Total RNA from light-density mononuclear AML patient samples as well as similar samples from healthy volunteers was isolated, and Per2 expression levels were determined by real time RT-PCR. We found that in 42 % of AML patient samples, Per2 mRNA expression levels were significantly lower (p<0.05) in comparison with levels in normal bone marrow cells (Fig. 5) .
Expression of Per2 leads to growth arrest
Further studies explored the consequences of expressing Per2 on cell proliferation. The CML, K562 and the myelomonocytic, U937, human cell lines were transfected either with a V5-tagged Per2 expression vector, or an empty vector as control.
After a short period of antibiotic selection, equal numbers of polyclonal populations were
in fresh media and their growth rate was measured by daily viable cell counts. In both cell lines, forced expression of Per2 led to a dramatic decrease in proliferation (Fig.   6B) . Expression of the Per2 protein was verified by Western analysis (Fig. 6A) .
To analyze additionally the role of Per2 in cell proliferation, we established an inducible cell line system. The K562 cell line was stably trnasfected with a zinc inducible V5-tagged Per2 expression vector (pMTPer2), as well as control empty vector (pMT).
Clones were selected on the basis of G418 resistance and inducibility of Per2 expression was demonstrated by Western blot (Fig. 6C) . Induction of Per2 led to very substantial growth reduction as measured by MTT assays (Fig. 6D ).
Cell cycle analysis was carried out to determine which phase of the cell cycle is inhibited by Per2 expression. After 3 days of culture in the presence of zinc, the K562- (Fig. 7B) .
We next examined the effect of Per2 expression on anchorage-independent clonal growth of K562 in soft agar (Fig. 7C) . Incubation of the K562-pMTPer2 cells in zinccontaining media led to complete inhibition of colony formation (0 colonies). Exposure of the K562-pMT control cells to zinc also inhibited colony formation compared with the wild type untreated cells, but to a significantly lesser extent.
Discussion
As one approach for better understanding the full extent of gene expression under the control of C/EBP proteins, we performed transcriptional profiling with NIH 3T3 cells ectopically expressing either C/EBP , C/EBP , C/EBP or C/EBP . Several C/EBP microarray studies using a number of cell types were previously reported (12, (39) (40) (41) . We elected to use NIH 3T3 cells because they do not express endogenous C/EBP proteins.
Furthermore, these multipotential mesenchymal stem cells have the capacity to express genes normally restricted to more differentiated cell types such as adipocytes, myocytes, granulocytes and neuronal cells (42) (43) (44) (45) (46) ; using them allowed induction of numerous C/EBP target genes from heterologous cell types.
An interesting question is whether C/EBP family members regulate specific genes or if they regulate a common set of genes. One major finding of our study is that almost all identified genes were regulated by more than one of the C/EBP members, albeit at different levels. These results suggest that strict C/EBP target gene specificity is rare; rather, specificity may be conveyed by how efficiently they can activate a given target gene. Of the four C/EBP examined, C/EBP was notably the strongest transcriptional modulator. In further studies, we focused mainly on C/EBP regulated genes.
While a number of genes identified by our screen were common to C/EBP targets Functional annotation analysis suggested a previously unreported relationship between C/EBP transcription factors and the circadian clock. Our microarry data identified three circadian genes, Per2, Rev-Erb and DBP as novel C/EBP targets (Fig.   8 ). This finding is especially intriguing given recent reports that link the circadian clock Clock genes are expressed in several peripheral tissues including bone marrow where they control cell proliferation and apoptosis by regulating genes involved in those processes (20) (21) (22) (23) (24) (25) (26) 53) . To investigate whether Per2 is involved in leukemia, we measured its expression in normal bone marrow and bone marrow from AML patients. Our results show that Per2 expression is reduced in 42% of AML samples. Casein kinase I (CKI ), a core component of the circadian system, regulates the stability of Per by phosphorylating these proteins. A recent report showed that CKI is essential for granulocytic differentiation (53) . Perhaps the decreased activity of Per2 in leukemic cells, which are blocked in their terminal differentiation, occurs not only by downregulation of its mRNA but also by a post-transcriptional mechanism such as phosphorylation.
We showed that forced expression of Per2 in K562 and U937 human myeloid leukemia cell lines leads to a marked growth inhibition. We also generated a stably transfected K562 line containing an inducible Per2 gene. Induction of Per2 in this cell A significant number of Per2 mutant mice die before the age of 16 months from spontaneous lymphomas (26) . We found that Per2 expression is downregulated in several types of human B-ALL and lymphoma cell lines, suggesting that inactivation of Per2 may contribute to the development of B-cell leukemias and lymphomas in humans. We also found that Per2 inhibits the proliferation of several epithelial cell types including breast, prostate and lung cancer cells (data not shown). C/EBP is expressed in normal epithelial cells from a variety of tissues and was recently suggested to act as a tumor suppressor gene in those cells (56) (57) (58) . Perhaps, induction of Per2 is one of the pathways contributing to antitumorgenic effects of C/EBP . These findings further support a role for Per2 as a potent growth inhibitor in a variety cell types.
For
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Rev-Erb , the second clock gene identified by our transcriptional profiling, is a transcriptional repressor that plays a key role in the circadian clock feedback loops. A recent report showed an association between Rev-Erb and ERBB2 expression levels in breast cancer samples (59) , suggesting that deregulation of Rev-Erb plays a role in cancer. The third circadian gene that we identified, Dbp, is not one of the core clock genes but is a component of the clock output system (60). Our microarray data showed that DBP expression is induced by C/EBP , repressed by C/EBP and is unaffected by either C/EBP or C/EBP . This is in agreement with an earlier study showing that although the DBP promoter contains C/EBP binding sites, C/EBP does not regulate its expression (61) . DBP is a member of the PAR bZIP transcription factor family that binds a subset of C/EBP sites (38) . Indeed, we were able to show that DBP positively regulates the Per2 promoter. More detailed studies are needed to determine whether DBP and C/EBPs regulate Per2 expression through a common element in the Per2 promoter.
In summary, our transcriptional profile study identified C/EBP-target genes, many of which were not previously associated with the C/EBP family. These studies identified for the first time, a link between C/EBPs and circadian clock genes. We showed that C/EBP , a bone fide tumor suppressor gene in leukemias, directly upregulates Per2 expression in hematopoietic cells. Additional studies of Per2 showed that its expression is reduced in AML samples, and that forced expression of this gene inhibits leukemic cell growth. These data support a model in which Per2, and possibly other clock genes, is 
